| Cat.No. | Name | Information |
|---|---|---|
| M3517 | Lapatinib | Lapatinib (GW572016) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. |
| M1802 | Lapatinib ditosylate monohydrate | Lapatinib (GW572016) ditosylate monohydrate is a selective and effective inhibitor of EGFR kinase (Ki = 3 nM), ErbB-2 kinase (Ki = 13 nM) and ErbB-4 kinase (Ki = 347 nM). |
| M1749 | Gefitinib | Gefitinib (ZD1839) is an EGFR tyrosine kinase and Akt phosphorylation inhibitor. Gefitinib significantly down-regulates CD47 expression and increases DC phagocytosis in non-small cell lung cancer cells such as PC9, H1437 and H1573. Gefitinib combined with CD47 antibody can enhance the phagocytosis of macrophages. |
| M5621 | Erlotinib (CP-358774) | Erlotinib (CP-358774) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
| M1913 | Neratinib | Neratinib (HKI-272) is an orally available, irreversible inhibitor of Her 2 tyrosine kinase. |
| M1850 | WZ4002 | WZ4002 is a novel, selective EGFR kinase inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) with IC50 of 8 nM. |
| M1869 | Dacomitinib | Dacomitinib (PF-00299804) is an oral, irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases. |
| M5307 | Afatinib dimaleate | Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. |
| M2424 | AZD9291 (Osimertinib) | Osimertinib (AZD-9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR, respectively. |
| M1677 | Afatinib | Afatinib (BIBW 2992) is a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor. |
| M56424 | SJF-1528 | SJF-1528 is a potent EGFR PROTAC degrader with DC50 values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutated EGFR in HeLa cells. |
| M56423 | CH7233163 | CH7233163 is a noncovalent ATP-competitive inhibitor for EGFR-Del19/T790M/C797S. |
| M56422 | ZN-A-1041 | ZN-A-1041 inhibits HER2 in BT474 cell and wt-EGFR in H838 cells, with IC50s of 9.5 nM and 12 μM respectively. |
| M56421 | EGFR-IN-5 | EGFR-IN-5 is a EGFR inhibitor with IC50s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFRL858R, EGFRL858R/T790M, and EGFRL858R/T790M/C797S, respectively. |
| M56420 | JBJ-09-063 | JBJ-09-063 is a mutant-selective allosteric EGFR inhibitor with IC50s of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM for EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S. |
| M56419 | EGFR-IN-99 | EGFR-IN-99 is a potent EGFR and HER2 Exon 20 insertion mutant inhibitor. |
| M56418 | EGFR-IN-80 | EGFR-IN-80 is an EGFR inhibitor with a pIC50 of 10.6. |
| M56417 | EGFR-IN-16 | EGFR-IN-16 is a potent EGFR inhibitor with pIC50 of 4.85 and 4.74 for EGFR and HER-2, respectively. |
| M56416 | Theliatinib | Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective EGFR inhibitor with a Ki of 0.05 nM and an IC50 of 3 nM. |
| M56415 | Pebezertinib | Pebezertinib (BLU 451) is an orally active inhibitor for EGFR. |
| M56414 | PKI-166 hydrochloride | PKI-166 hydrochloride is a potent, selective and orally active EGFR tyrosine kinase inhibitor, with an IC50 of 0.7 nM. |
| M56413 | JNJ28871063 hydrochloride | JNJ28871063 hydrochloride is an orally active, highly selective and ATP competitive pan-ErbB kinase inhibitor with IC50 values of 22 nM, 38 nM, and 21 nM for ErbB1, ErbB2, and ErbB4, respectively. |
| M56412 | BIBX 1382 dihydrochloride | BIBX 1382 dihydrochloride is an ErbB kinase inhibitor with significant antiviral activity. |
| M56411 | BMS-599626 dihydrochloride | BMS-599626 dihydrochloride is a small molecule pan-HER (human epidermal growth factor receptor) kinase inhibitor. |
| M55660 | MTX-531 | MTX-531 is a first-in-class, potent and selective inhibitor of EGFR and PI3K, with IC50s of 14.7 nM and 1.1-233 nM (differ in subtype). MTX-531 can also act as a weak agonist of PPARγ, with the EC50 of 3.4 μM in 293H cells. |
| M55046 | Inetetamab | Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab shows antitumor activities when used alone or together with tyrosine kinase inhibitors. |
| M54703 | BBT-207 | BBT-207 is a reversible, mutant-specific EGFR inhibitor with antitumor activity. |
| M54702 | VRN-11 | VRN-11 is an EGFR C797S inhibitor. |
| M54701 | TRX-221 | TRX-221 is an EGFR C797S inhibitor. |
| M54700 | TAS-3351 | TAS-3351 is an EGFR C797S inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
